Meetings - The ASCO Post

Oncology drug labels, especially those that have been on the market for more than 15 years, may not always be up-to-date. Critical data about safety, efficacy, or prescribing information may be mis...

By Margot J. Fromer / December 25, 2017 / Friends of Cancer Research Annual Meeting

Data Must Be Generated to Support Cross-Labeling of Combination Therapies for Cancer

Combinations of targeted therapies (triple, quadruple, or even more) are part of the future of cancer treatment, which means that traditional clinical trials will have to be streamlined and updated to...

Issues in Oncology

By Margot J. Fromer / December 25, 2017 / Friends of Cancer Research Annual Meeting

FDA Helps Streamline Approval Process for Supplemental Drug Indications

As researchers learn more about the natural history of cancers, as more drugs are effective for more types of the disease, and as the number and complexity of combination therapies increase, the more ...

Friends of Cancer Research Annual Meeting

Up-to-Date Labels for Older Drugs Essential for Appropriate Use

Data Must Be Generated to Support Cross-Labeling of Combination Therapies for Cancer

FDA Helps Streamline Approval Process for Supplemental Drug Indications

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC